Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a
company focused on developing, marketing, and selling a variety of
men’s health and wellness products in the areas of erectile
dysfunction (ED), hair growth, weight loss, and hormone replacement
therapies, is pleased to announce that its CEO, Jacob Cohen, was
recently featured on Benzinga All-Access.
CLICK HERE TO WATCH THE COMPLETE INTERVIEW.
In the interview with Zunaid Suleman, Cohen
discussed Mangoceuticals' strategic direction, recent developments,
expanding product offerings, and plans for global expansion. He
emphasized the company's commitment to innovation and excellence in
the health and wellness industry, highlighting the launch of new
products designed to meet the evolving needs of consumers
worldwide. Cohen also provided insights into the significant growth
opportunities within the health and wellness sector, particularly
in emerging global markets.
"We are thrilled to be featured on Benzinga
All-Access and to share our vision and plans with a wider
audience," said Jacob Cohen. "Our commitment to innovation,
quality, and global growth is stronger than ever. We are excited
about the future and the opportunities that lie ahead as we
continue to expand our product offerings and reach new
markets."
About MangoRx
MangoRx is focused on developing a variety of
men's health and wellness products and services via a secure
telemedicine platform. To date, the Company has identified men's
wellness telemedicine services and products as a growing sector and
especially related to the area of erectile dysfunction (ED), hair
growth and hormone replacement therapies. Interested consumers can
use MangoRx’s telemedicine platform for a smooth experience.
Prescription requests will be reviewed by a physician and, if
approved, fulfilled and discreetly shipped through MangoRx’s
partner compounding pharmacy and right to the patient’s doorstep.
To learn more about MangoRx’s mission and other products, please
visit www.MangoRx.com or on social media @Mango.Rx.
Cautionary Note Regarding
Forward-Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 (“forward-looking
statements”). These forward-looking statements represent the
Company’s current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as “estimate,” “expects,” “project,” “believe,” “anticipate,”
“intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target”
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company’s control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, our ability to meet Nasdaq’s
minimum bid price requirement and other continued listing
requirements of Nasdaq; the Company’s stockholders’ equity as of
the Company’s next fiscal quarter end, which is required to be
above $2.5 million pursuant to correspondence from Nasdaq; our
ability to maintain the listing of our common stock on Nasdaq; our
ability to commercialize our patent portfolio; our ability to
obtain Comisión Federal para la Protección contra Riesgos
Sanitarios for our ED product in Mexico, the costs thereof and
timing associated therewith; our ability to obtain additional
funding and generate revenues to support our operations; risks
associated with our ED product which have not been, and will not
be, approved by the U.S. Food and Drug Administration (“FDA”) and
have not had the benefit of the FDA’s clinical trial protocol which
seeks to prevent the possibility of serious patient injury and
death; risks that the FDA may determine that the compounding of our
planned products does not fall within the exemption from the
Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by
Section 503A; risks associated with related party relationships and
agreements; the effect of data security breaches, malicious code
and/or hackers; competition and our ability to create a well-known
brand name; changes in consumer tastes and preferences; material
changes and/or terminations of our relationships with key parties;
significant product returns from customers, product liability,
recalls and litigation associated with tainted products or products
found to cause health issues; our ability to innovate, expand our
offerings and compete against competitors which may have greater
resources; our significant reliance on related party transactions;
the projected size of the potential market for our technologies and
products; risks related to the fact that our Chairman and Chief
Executive Officer, Jacob D. Cohen has significant voting control
over the Company; risks related to the significant number of shares
in the public float, our share volume, the effect of sales of a
significant number of shares in the marketplace, and the fact that
the majority of our shareholders paid less for their shares than
the public offering price of our common stock in our recent initial
public offering; dilution caused by recent offerings; conversion of
outstanding shares of preferred stock and the rights and
preferences thereof, the fact that we have a significant number of
outstanding warrants to purchase shares of common stock and other
convertible securities, the resale of which underlying shares have
been registered under the Securities Act of 1933, as amended,
dilution caused by exercises/conversions thereof, overhang related
thereto, and decreases in the trading price of our common stock
caused by sales thereof; our ability to build and maintain our
brand; cybersecurity, information systems and fraud risks and
problems with our websites; changes in, and our compliance with,
rules and regulations affecting our operations, sales, marketing
and/or our products; shipping, production or manufacturing delays;
regulations we are required to comply with in connection with our
operations, manufacturing, labeling and shipping; our dependency on
third-parties to prescribe and compound our ED product; our ability
to establish or maintain relations and/or relationships with
third-parties; potential safety risks associated with our products,
including the use of ingredients, combination of such ingredients
and the dosages thereof; the effects of changing rates of inflation
and interest rates, and economic downturns, including potential
recessions, as well as macroeconomic, geopolitical, health and
industry trends, pandemics, acts of war (including the ongoing
Ukraine/Russian conflict and war in Israel) and other large-scale
crises; our ability to protect intellectual property rights; our
ability to attract and retain key personnel to manage our business
effectively; overhang which may reduce the value of our common
stock; volatility in the trading price of our common stock; and
general consumer sentiment and economic conditions that may affect
levels of discretionary customer purchases of the Company’s
products, including potential recessions and global economic
slowdowns. Although we believe that our plans, intentions and
expectations reflected in or suggested by the forward-looking
statements we make in this release are reasonable, we provide no
assurance that these plans, intentions or expectations will be
achieved. Consequently, you should not consider any such list to be
a complete set of all potential risks and uncertainties.
More information on potential factors that could
affect the Company’s financial results is included from time to
time in the “Cautionary Note Regarding Forward-Looking Statements,”
“Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” sections of the
Company’s filings with the SEC, including the Company’s Annual
Report on Form 10-K for the year ended December 31, 2023 and our
Quarterly Report on Form 10-Q for the three months ended March 31,
2024, and subsequent reports. These filings are available
at www.sec.gov and at our website
at https://www.mangoceuticals.com/sec-filings. All subsequent
written and oral forward-looking statements attributable to the
Company or any person acting on behalf of the Company are expressly
qualified in their entirety by the cautionary statements referenced
above. Other unknown or unpredictable factors also could have
material adverse effects on the Company’s future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow MangoRx on social
media:https://www.instagram.com/mango.rxhttps://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial
FOR INVESTOR RELATIONSMangoceuticals Investor
RelationsEmail: investors@mangorx.com
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Aug 2023 to Aug 2024